Compare Diageo plc (DEO) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Illumina, Inc. — how do they compare? Diageo plc trades at $86.55 (market cap $47.67B), while Illumina, Inc. trades at $267.69 (market cap $39.95B). The key difference: Diageo plc is the larger of the two by market cap, and Diageo plc pays a 2.3% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Illumina, Inc. for 83 Days on average.
| DEO | ILMN | |
|---|---|---|
Market Cap | $47.67B | $39.95B |
Volume | 893,372 | 3,169,503 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $293.69 |
52-Week Low | $72.47 | $91.00 |
Typical Hold Time | 66 Days | 83 Days |
Enterprise Value | $68.09B | $41.31B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.82, up 2.47% with bullish technical signals and strong analyst support. The stock shows solid fundamentals with consistent earnings beats, a 15.82% ROE, and improving cash flow trends. Recent corporate developments include a new CFO appointment and marketing initiatives supporting brand strength amid ongoing US business restructuring.
The outlook remains positive with 49% analyst buy ratings and cost-saving initiatives driving margin improvement. Key risks include US market volatility and regulatory challenges in India. The stock presents a compelling turnaround story with valuation support at current levels.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
